CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Diane E. Gingrich et al.|PubMed|2003Cited by 124
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicitySheila Miknyoczki, Bruce Ruggeri, Hong Chang et al.|Molecular Cancer Therapeutics|2007Cited by 112
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cellsWeihua Wan, Mangeng Cheng, Mark S. Albom et al.|Blood|2005Cited by 105
Mixed lineage kinase activity of indolocarbazole analoguesChikara Murakata, Robert L. Hudkins, Masami Kaneko et al.|Bioorganic & Medicinal Chemistry Letters|2002Cited by 94
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055Diane E. Gingrich, Robert L. Hudkins, D. Rajagopala Reddy et al.|Journal of Medicinal Chemistry|2003Cited by 74